Ibrutinib ( DrugBank: Ibrutinib )

3 diseases

28. 全身性アミロイドーシス

臨床試験数 : 267 / 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03130348 (ClinicalTrials.gov)	March 15, 2018	21/4/2017	IbrutinibWith or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refracto ...	Phase II Study of IbrutinibWith or Without Bortezomib and Dexamethasone for the Treatment of Patient ...	Amyloidosis;Immunoglobulin Light Chain Deposition	Drug: Bortezomib;Drug: Dexamethasone;Drug: Ibrutinib;Other: Laboratory Biomarker Analysis	Mayo Clinic	National Cancer Institute (NCI)	Withdrawn	18 Years	N/A	All	0	Phase 2	United States

臨床試験数 : 245 / 薬物数 : 318 - (DrugBank : 86) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 166

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04439006 (ClinicalTrials.gov)	October 23, 2020	17/6/2020	Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization	Randomized Double-Blind Phase 2 Trial of IbrutinibVersus Standard Treatment for COVID-19 Illness Req ...	Aplastic Anemia;Hematopoietic and Lymphoid Cell Neoplasm;Malignant Solid Neoplasm;Monoclonal B-Cell ...	Other: Best Practice;Drug: Ibrutinib	Jennifer Woyach	Janssen Scientific Affairs, LLC	Active, not recruiting	18 Years	N/A	All	10	Phase 2	United States

臨床試験数 : 146 / 薬物数 : 131 - (DrugBank : 59) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 158

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04398459 (ClinicalTrials.gov)	May 1, 2020	18/5/2020	The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia	A Phase II, Multicenter, Open-label Trial to Determine the Safety and Efficacy of Ibrutinibin Refrac ...	Refractory/Relapsed Autoimmune Hemolytic Anemia	Drug: Ibrutinib	Institute of Hematology & Blood Diseases Hospital	NULL	Recruiting	6 Years	70 Years	All	18	Phase 2	China
2	NCT03827603 (ClinicalTrials.gov)	February 21, 2017	24/1/2019	Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia	Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia: ELaboration of Treatment Approach	AIHA - Warm Autoimmune Hemolytic Anemia	Drug: Ibrutinib	Eugene Nikitin	NULL	Active, not recruiting	18 Years	N/A	All	50	Phase 2	Russian Federation